




Instance: composition-en-78817b35263746b79687cd6c5a122f9f
InstanceOf: CompositionUvEpi
Title: "Composition for memantine Package Leaflet"
Description:  "Composition for memantine Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/13/836/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp78817b35263746b79687cd6c5a122f9f)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - memantine"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Memantine ratiopharm is and what it is used for </li>
<li>What you need to know before you take Memantine ratiopharm </li>
<li>How to take Memantine ratiopharm </li>
<li>Possible side effects </li>
<li>How to store Memantine ratiopharm </li>
<li>Contents of the pack and other information </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What memantine is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What memantine is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>How does Memantine ratiopharm work 
Memantine ratiopharm contains the active substance memantine hydrochloride. It belongs to a group 
of medicines known as anti-dementia medicines. 
Memory loss in Alzheimer s disease is due to a disturbance of message signals in the brain. The brain 
contains so-called N-methyl-D-aspartate (NMDA)-receptors that are involved in transmitting nerve 
signals important in learning and memory. Memantine ratiopharm belongs to a group of medicines 
called NMDA-receptor antagonists. Memantine ratiopharm acts on these NMDA-receptors improving 
the transmission of nerve signals and the memory. </p>
<p>What is Memantine ratiopharm used for 
Memantine ratiopharm is used for the treatment of patients with moderate to severe Alzheimer s 
disease. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take memantine"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take memantine"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Memantine ratiopharm 
  if you are allergic to memantine hydrochloride, peanut or soya or any of the other ingredients of 
this medicine (listed in section 6). </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking Memantine ratiopharm 
  if you have a history of epileptic seizures. 
  if you have recently experienced a myocardial infarction (heart attack), or if you are suffering from 
congestive heart failure or from an uncontrolled hypertension (high blood pressure). 
In these situations the treatment should be carefully supervised, and the clinical benefit of Memantine 
ratiopharm reassessed by your doctor on a regular basis. </p>
<p>If you suffer from renal impairment (kidney problems), your doctor should closely monitor your 
kidney function and if necessary adapt the memantine doses accordingly. </p>
<p>The use of medicinal products called 
  amantadine (for the treatment of Parkinson s disease), 
  ketamine (a substance generally used as an anaesthetic), 
  dextromethorphan (generally used to treat cough) and 
  other NMDA-antagonists 
at the same time should be avoided. </p>
<p>Children and adolescents 
Memantine ratiopharm is not recommended for children and adolescents under the age of 18 years. </p>
<p>Other medicines and Memantine ratiopharm 
Tell your doctor or pharmacist if you are taking/using, have recently taken/used or might take/use any 
other medicines. </p>
<p>In particular, Memantine ratiopharm may change the effects of the following medicines and their dose 
may need to be adjusted by your doctor: 
  amantadine, ketamine, dextromethorphan 
  dantrolene, baclofen 
  cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine 
  hydrochlorothiazide (or any combination with hydrochlorothiazide) 
  anticholinergics (substances generally used to treat movement disorders or intestinal cramps) 
  anticonvulsants (substances used to prevent and relieve seizures) 
  barbiturates (substances generally used to induce sleep) 
  dopaminergic agonists (substances such as L-dopa, bromocriptine) 
  neuroleptics (substances used in the treatment of mental disorders) 
  oral anticoagulants </p>
<p>If you go into hospital, let your doctor know that you are taking Memantine ratiopharm. </p>
<p>Memantine ratiopharm with food and drink 
You should inform your doctor if you have recently changed or intend to change your diet 
substantially (e.g. from normal diet to strict vegetarian diet) or if you are suffering from states of renal 
tubulary acidosis (RTA, an excess of acid-forming substances in the blood due to renal dysfunction 
(poor kidney function)) or severe infections of the urinary tract (structure that carries urine), as your 
doctor may need to adjust the dose of your medicine. </p>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. </p>
<p>The use of memantine in pregnant women is not recommended. </p>
<p>Women taking Memantine ratiopharm should not breast-feed. </p>
<p>Driving and using machines 
Your doctor will tell you whether your illness allows you to drive and to use machines safely. 
Also, Memantine ratiopharm may change your reactivity, making driving or operating machinery 
inappropriate. </p>
<p>Memantine ratiopharm contains lactose and soya lecithin 
This medicine contains lactose. If you have been told by your doctor that you have an intolerance to 
some sugars, contact your doctor before taking this medicinal product. 
This medicine contains soya lecithin. If you are allergic to peanut or soya, do not take this medicinal 
product. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take memantine"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take memantine"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. </p>
<p>Dosage 
The recommended dose of Memantine ratiopharm for adults and older patients is 20 mg once a day. In 
order to reduce the risk of side effects this dose is achieved gradually by the following daily treatment 
scheme: </p>
<p>week 1 
half a 10 mg tablet 
week 2 
one 10 mg tablet 
week 3 
one and a half 10 mg tablets 
week 4 and beyond 
two 10 mg tablets once a day </p>
<p>The usual starting dose is half a tablet once a day (1x 5 mg) for the first week. This is increased to one 
tablet once a day (1x 10 mg) in the second week and to one and a half tablets once a day in the third 
week. From the fourth week on, the usual dose is two tablets once a day (1x 20 mg). </p>
<p>The tablet can be divided into equal doses. </p>
<p>Dosage in patients with impaired kidney function 
If you have impaired kidney function, your doctor will decide upon a dose that suits your condition. In 
this case, monitoring of your kidney function should be performed by your doctor at specified 
intervals. </p>
<p>Administration 
Memantine ratiopharm should be administered orally once a day. To benefit from your medicine you 
should take it regularly every day at the same time of the day. 
The tablets should be swallowed with some water. The tablets can be taken with or without food. </p>
<p>Duration of treatment 
Continue to take Memantine ratiopharm as long as it is of benefit to you. Your doctor should assess 
your treatment on a regular basis. </p>
<p>If you take more Memantine ratiopharm than you should 
  In general, taking too much Memantine ratiopharm should not result in any harm to you. You may 
experience increased symptoms as described in section 4.  Possible side effects . 
  If you take a large overdose of Memantine ratiopharm, contact your doctor or get medical advice, 
as you may need medical attention. </p>
<p>If you forget to take Memantine ratiopharm 
  If you find you have forgotten to take your dose of Memantine ratiopharm, wait and take your next 
dose at the usual time. 
  Do not take a double dose to make up for a forgotten dose. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>In general, the observed side effects are mild to moderate. 
Common (affects 1 to 10 users in 100): 
  Headache, sleepiness, constipation, elevated liver function tests, dizziness, balance disorders, 
shortness of breath, high blood pressure and drug hypersensitivity </p>
<p>Uncommon (affects 1 to 10 users in 1,000): 
  Tiredness, fungal infections, confusion, hallucinations, vomiting, abnormal gait, heart failure and 
venous blood clotting (thrombosis/thromboembolism) </p>
<p>Very Rare (affects less than 1 user in 10,000): 
  Seizures </p>
<p>Not known (frequency cannot be estimated from the available data): 
  Inflammation of the pancreas, inflammation of the liver (hepatitis) and psychotic reactions </p>
<p>Alzheimer s disease has been associated with depression, suicidal ideation and suicide. These events 
have been reported in patients treated with memantine. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store memantine"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store memantine"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and the blister pack after 
EXP. The expiry date refers to the last day of that month. </p>
<p>Blister packs 
Do not store above 25  C. </p>
<p>HDPE bottles 
This medicinal product does not require any special storage conditions. 
Shelf life after first opening of the container: 6 months </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Memantine ratiopharm contains 
- The active substance is memantine hydrochloride. 
Each film-coated tablet contains 10 mg memantine hydrochloride equivalent to 8.31 mg 
memantine. 
- The other ingredients are: 
Tablet core 
Cellulose microcrystalline (E 460), starch pregelatinised (E 1404), lactose, colloidal anhydrous 
silica (E 551), magnesium stearate (E 470b). 
Coating 
Polysorbate 80 (E 433), polyvinyl alcohol (E 1203), titanium dioxide (E 171), talc (E 553b), 
soya lecithin (E 322), xanthan gum (E 415). </p>
<p>What Memantine ratiopharm looks like and contents of the pack 
White to off-white, capsule shaped, biconvex tablets with a break score on one side and debossed with 
 10  on the other side. </p>
<p>Memantine ratiopharm is available in packs of 10, 14, 21, 28, 30, 42, 50, 56, 98, 100 and 112 film-
coated tablets. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
ratiopharm GmbH 
Graf-Arco-Stra e 3 
89079 Ulm 
Germany </p>
<p>Manufacturer 
Merckle GmbH 
Ludwig-Merckle-Stra e 3 
89143 Blaubeuren 
Germany </p>
<p>TEVA Pharmaceutical Works Private Limited Company 
Pallagi  t 13, 4042 Debrecen 
Hungary </p>
<p>HBM Pharma s.r.o. 
Slabinsk  30, 03680 Martin 
Slovakia </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Teva Pharma Belgium N.V./S.A./AG 
T l/Tel: +32 38207Lietuva 
UAB Teva Baltics 
Tel: +370 52660  </p>
<p>: +359 24899Luxembourg/Luxemburg 
ratiopharm GmbH 
Allemagne/Deutschland 
T l/Tel: +49 73140 esk  republika 
Teva Pharmaceuticals CR, s.r.o. 
Tel: +420 251007Magyarorsz g 
Teva Gy gyszergy r Zrt. 
Tel: +36 12886Danmark 
Teva Denmark A/S 
Tlf: +45 44985Malta 
Teva Pharmaceuticals Ireland 
L-Irlanda 
Tel: +44 2075407Deutschland 
ratiopharm GmbH 
Tel: +49 73140Nederland 
Teva Nederland B.V. 
Tel: +31 8000228Eesti 
UAB Teva Baltics Eesti filiaal 
Tel: +372 6610Norge 
Teva Norway AS 
Tlf: +47 66775<br />
Specifar A.B.E.E. 
 : +30 2118805 sterreich 
ratiopharm Arzneimittel Vertriebs-GmbH 
Tel: +43 1970Espa a 
Teva Pharma, S.L.U. 
Tel: +34 913873Polska 
Teva Pharmaceuticals Polska Sp. z o.o. 
Tel: +48 223459France 
Teva Sant<br />
T l: +33 155917Portugal 
ratiopharm - Com rcio e Ind stria de Produtos 
Farmac uticos, Lda. 
Tel: +351 214767Hrvatska 
Pliva Hrvatska d.o.o. 
Tel: +385 13720Rom nia 
Teva Pharmaceuticals S.R.L. 
Tel: +40 212306Ireland 
Teva Pharmaceuticals Ireland 
Tel: +44 2075407Slovenija 
Pliva Ljubljana d.o.o. 
Tel: +386 15890 sland 
Alvogen ehf. 
S mi: +354 5222Slovensk  republika 
TEVA Pharmaceuticals Slovakia s.r.o. 
Tel: +421 257267Italia 
Teva Italia S.r.l. 
Tel: +39 028917Suomi/Finland 
Teva Finland Oy 
Puh/Tel: +358 201805<br />
Specifar A.B.E.E. </p>
<p>: +30 2118805Sverige 
Teva Sweden AB 
Tel: +46 42121Latvija 
UAB Teva Baltics fili le Latvij<br />
Tel: +371 67323United Kingdom (Northern Ireland) 
Teva Pharmaceuticals Ireland 
Ireland 
Tel: +44 2075407This leaflet was last revised in </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p> </div>"""      



Instance: composition-da-78817b35263746b79687cd6c5a122f9f
InstanceOf: CompositionUvEpi
Title: "Composition for memantine Package Leaflet"
Description:  "Composition for memantine Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/13/836/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp78817b35263746b79687cd6c5a122f9f)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - memantine"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal De vide, før De begynder at tage Memantine ratiopharm </li>
<li>Sådan skal De tage Memantine ratiopharm </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What memantine is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What memantine is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvordan virker Memantine ratiopharm? 
Memantine ratiopharm indeholder det aktive stof memantinhydrochlorid. Det tilhører gruppen af 
medicin kaldet antidemensmedicin (medicin til behandling af demens). 
Hukommelsestab ved Alzheimers sygdom skyldes en forstyrrelse af signalstoffer i hjernen. Hjernen 
indeholder såkaldte N-methyl-D-aspartat (NMDA)-receptorer, der er involveret i overførslen af 
nervesignaler, som er vigtige for indlæring og hukommelse. Memantine ratiopharm hører til en gruppe 
af lægemidler kaldet NMDA-receptor-antagonister. Memantine ratiopharm indvirker på disse 
NMDA-receptorer og forbedrer overførslen af nervesignaler samt hukommelsen. </p>
<p>Hvad anvendes Memantine ratiopharm til? 
Memantine ratiopharm anvendes til behandling af patienter med moderat til svær Alzheimers sygdom. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take memantine"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take memantine"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Memantine ratiopharm </p>
<ul>
<li>hvis De er allergisk over for memantinhydrochlorid, jordnødder eller soja eller et af de øvrige 
indholdsstoffer i Memantine ratiopharm (angivet i punkt 6). </li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før De tager Memantine ratiopharm </p>
<ul>
<li>
<p>hvis De tidligere har haft epileptiske anfald </p>
</li>
<li>
<p>hvis De for nylig har haft blodprop i hjertet (myokardieinfarkt), eller hvis De lider af dårligt 
hjerte eller ukontrolleret forhøjet blodtryk (hypertension). 
I disse situationer bør behandlingen overvåges nøje, og den kliniske gavn af Memantine ratiopharm 
skal regelmæssigt vurderes af Deres læge. </p>
</li>
</ul>
<p>Hvis De har nedsat nyrefunktion (nyreproblemer), bør Deres læge nøje overvåge Deres nyrefunktion 
og om nødvendigt tilpasse memantin-dosen derefter. </p>
<p>Samtidig brug af lægemidler ved navn </p>
<ul>
<li>
<p>amantadin (til behandling af Parkinsons sygdom) </p>
</li>
<li>
<p>ketamin (et middel, der anvendes til bedøvelse) </p>
</li>
<li>
<p>dextromethorfan (anvendes generelt til behandling af hoste) og </p>
</li>
<li>
<p>andre NMDA-antagonister 
bør undgås. </p>
</li>
</ul>
<p>Børn og unge 
Memantine ratiopharm anbefales ikke til børn og unge under 18 år. </p>
<p>Brug af anden medicin sammen med Memantine ratiopharm 
Fortæl det altid til lægen eller apotekspersonalet, hvis De tager/bruger anden medicin eller har gjort 
det for nylig. </p>
<p>I særdeleshed kan Memantine ratiopharm ændre virkningen af følgende lægemidler, og lægen kan 
derfor være nødt til at ændre doseringen: </p>
<ul>
<li>
<p>amantadin, ketamin, dextromethorfan </p>
</li>
<li>
<p>dantrolen, baklofen </p>
</li>
<li>
<p>cimetidin, ranitidin, procainamid, quinidin, quinin, nikotin </p>
</li>
<li>
<p>hydrochlorothiazid (eller en hvilken som helst kombination med hydrochlorothiazid) </p>
</li>
<li>
<p>antikolinergika (stoffer, der generelt bruges til behandling af lidelser i bevægeapparatet eller 
tarmkramper) </p>
</li>
<li>
<p>antikonvulsiva (stoffer, der bruges til at forebygge og afhjælpe krampeanfald) </p>
</li>
<li>
<p>barbiturater (stoffer, der generelt bruges som sovemidler) </p>
</li>
<li>
<p>dopaminerge agonister (stoffer såsom L-dopa, bromokriptin) </p>
</li>
<li>
<p>neuroleptika (stoffer, der bruges til behandling af sindslidelser) </p>
</li>
<li>
<p>orale antikoagulantia. </p>
</li>
</ul>
<p>Hvis De kommer på hospitalet, skal De sige til lægen, at De får Memantine ratiopharm. </p>
<p>Brug af Memantine ratiopharm sammen med mad og drikke 
De bør informere Deres læge, hvis De for nylig har ændret eller har i sinde at ændre Deres kost 
væsentligt (f.eks. fra en normal kost til en streng vegetarisk kost). De bør også informere Deres læge, 
hvis De lider af tilstande med renal tubulær acidose (RTA, overskud af syredannende stoffer i blodet 
på grund af nedsat nyrefunktion) eller alvorlige infektioner i urinvejene (som urinen udskilles 
igennem). Deres læge kan i så fald være nødt til at justere Deres medicindosis. </p>
<p>Graviditet og amning 
Hvis De er gravid eller ammer, har mistanke om, at De er gravid, eller planlægger at blive gravid, skal 
De spørge Deres læge eller apotekspersonalet til råds, før De tager dette lægemiddel. </p>
<p>Memantin anbefales ikke til gravide kvinder. </p>
<p>Kvinder, der tager Memantine ratiopharm, bør ikke amme. </p>
<p>Trafik- og arbejdssikkerhed 
Deres læge vil fortælle Dem, om Deres sygdom tillader, at De kan føre motorkøretøj eller og betjene 
maskiner på sikker vis. Memantine ratiopharm kan måske også påvirke Deres reaktionsevne, så det 
ikke er hensigtsmæssigt at føre motorkøretøj eller betjene maskiner. </p>
<p>Memantine ratiopharm indeholder lactose og sojalecithin 
Denne medicin indeholder lactose. Kontakt lægen, før De tager denne medicin, hvis lægen har fortalt 
Dem, at De ikke tåler visse sukkerarter. 
Denne medicin indeholder sojalecithin. De må ikke tage denne medicin, hvis De er overfølsom over 
for jordnødder eller soja. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take memantine"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take memantine"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er De i tvivl, så spørg lægen eller 
apotekspersonalet. </p>
<p>Dosering 
Den anbefalede dosis af Memantine ratiopharm til voksne og ældre patienter er 20 mg én gang dagligt. 
For at mindske risikoen for bivirkninger opnås denne dosis gradvist ud fra følgende daglige 
behandlingsskema: </p>
<ol>
<li>uge 
En halv tablet à 10 mg </li>
<li>uge 
En tablet à 10 mg </li>
<li>uge 
Halvanden tablet à 10 mg </li>
<li>uge og derefter 
To tabletter à 10 mg én gang dagligt  </li>
</ol>
<p>Den normale startdosis er en halv tablet en gang dagligt (1x 5 mg) i den første uge. Denne øges til en 
tablet én gang dagligt (1x 10 mg) i den anden uge og til halvanden tablet én gang dagligt i den tredje 
uge. Fra og med den fjerde uge er den normale dosis 2 tabletter én gang dagligt (1x 20 mg). </p>
<p>Tabletten kan deles i to lige store doser. </p>
<p>Dosis til patienter med nedsat nyrefunktion 
Hvis De har nedsat nyrefunktion, afgør Deres læge, hvilken dosis der passer til Deres tilstand. I så fald 
bør Deres læge overvåge Deres nyrefunktion regelmæssigt. </p>
<p>Administration 
Memantine ratiopharm bør indtages gennem munden en gang dagligt. De bør tage tabletterne 
regelmæssigt hver dag på samme tidspunkt af dagen for at opnå størst mulig virkning af tabletterne. 
Tabletterne bør synkes sammen med noget vand. Tabletterne kan tages sammen med eller uden mad. </p>
<p>Behandlingens varighed 
Bliv ved med at tage Memantine ratiopharm, så længe De har gavn af det. Deres læge bør 
regelmæssigt vurdere Deres behandling. </p>
<p>Hvis De har taget for meget Memantine ratiopharm </p>
<ul>
<li>
<p>Generelt burde indtagelse af for meget Memantine ratiopharm ikke være skadeligt for Dem. De 
kan opleve forøgede symptomer, som beskrevet i pkt. 4 “Bivirkninger". </p>
</li>
<li>
<p>Hvis De tager en stor overdosis af Memantine ratiopharm, skal De søge læge, da De kan have 
behov for medicinsk behandling. </p>
</li>
</ul>
<p>Hvis De har glemt at tage Memantine ratiopharm </p>
<ul>
<li>
<p>Hvis De har glemt at tage Deres dosis af Memantine ratiopharm, skal De vente og tage Deres 
næste dosis på det sædvanlige tidspunkt. </p>
</li>
<li>
<p>De må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
</li>
</ul>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, De er i tvivl om. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>De bivirkninger, der er set, er generelt milde til moderate. </p>
<p>Almindelige (påvirker 1-10 ud af 100 patienter): </p>
<ul>
<li>Hovedpine, søvnighed, forstoppelse, forhøjede værdier ved leverfunktionsprøver, svimmelhed, 
balanceforstyrrelser, kortåndethed, forhøjet blodtryk og overfølsomhed over for medicinen. </li>
</ul>
<p>Ikke almindelige (påvirker 1-10 ud af 1.000 patienter): </p>
<ul>
<li>Træthed, svampeinfektioner, forvirring, hallucinationer, opkastning, unormal gang, hjertesvigt 
og blodprop i en blodåre (vene). </li>
</ul>
<p>Meget sjældne (påvirker færre end 1 ud af 10.000 patienter): </p>
<ul>
<li>Krampeanfald. </li>
</ul>
<p>Ikke kendt (hyppigheden kan ikke estimeres ud fra forhåndenværende data): </p>
<ul>
<li>Betændelse i bugspytkirtlen, leverbetændelse (hepatitis) og psykotiske reaktioner. </li>
</ul>
<p>Alzheimers sygdom er blevet sat i forbindelse med depression, selvmordstanker og selvmord. Disse 
hændelser er blevet beskrevet hos patienter i behandling med memantin. </p>
<p>Indberetning af bivirkninger 
Hvis De oplever bivirkninger, bør De tale med Deres læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store memantine"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store memantine"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken og blisterpakningen efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Blisterpakninger 
Må ikke opbevares ved temperaturer over 25 °C. </p>
<p>HDPE-flasker 
Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. 
Opbevaringstiden efter første åbning af beholderen: 6 måneder. </p>
<p>Spørg apotekspersonalet, hvordan De skal bortskaffe medicinrester. Af hensyn til miljøet må De ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Memantine ratiopharm indeholder:</p>
<ul>
<li>
<p>Aktivt stof: Memantinhydrochlorid. 
Hver filmovertrukket tablet indeholder 10 mg memantinhydrochlorid svarende til 8,31 mg 
memantin. </p>
</li>
<li>
<p>Øvrige indholdsstoffer: 
Tabletkerne 
Cellulose, mikrokrystallinsk (E 460), stivelse, pregelatineret (E 1404), lactose, kolloid vandfri 
silica (E 551), magnesiumstearat (E 470b). </p>
</li>
</ul>
<p>Overtræk 
Polysorbat 80 (E 433), polyvinylalkohol (E 1203), titandioxid (E 171), talcum (E 553b), 
sojalecithin (E 322), xanthangummi (E 415). </p>
<p>Udseende og pakningsstørrelser </p>
<p>Hvide til off-white, kapselformede, bikonvekse tabletter med en delekærv på den ene side og præget 
med "10" på den anden side. </p>
<p>Memantine ratiopharm findes i pakninger på 10, 14, 21, 28, 30, 42, 50, 56, 98, 100 og 
112 filmovertrukne tabletter. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
ratiopharm GmbH 
Graf-Arco-Straße 3 
89079 Ulm 
Tyskland </p>
<p>Fremstiller 
Merckle GmbH 
Ludwig-Merckle-Straße 3 
89143 Blaubeuren 
Tyskland </p>
<p>TEVA Pharmaceutical Works Private Limited Company 
Pallagi út 13, 4042 Debrecen 
Ungarn </p>
<p>HBM Pharma s.r.o. 
Slabinská 30, 03680 Martin 
Slovakiet </p>
<p>Hvis De ønsker yderligere oplysninger om dette lægemiddel, skal De henvende Dem til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Teva Pharma Belgium N.V./S.A./AG 
Tél/Tel: +32 38207 
Lietuva 
UAB Teva Baltics 
Tel: +370 52660 
България 
Тева Фарма ЕАД 
Тел: +359 24899 
Luxembourg/Luxemburg 
ratiopharm GmbH 
Allemagne/Deutschland 
Tél/Tel: +49 73140 
Česká republika 
Teva Pharmaceuticals CR, s.r.o. 
Tel: +420 251007 
Magyarország 
Teva Gyógyszergyár Zrt. 
Tel: +36 12886 
Danmark 
Teva Denmark A/S 
Tlf: +45 44985 
Malta 
Teva Pharmaceuticals Ireland 
L-Irlanda 
Tel: +44 2075407 </p>
<p>Deutschland 
ratiopharm GmbH 
Tel: +49 73140 
Nederland 
Teva Nederland B.V. 
Tel: +31 8000228 
Eesti 
UAB Teva Baltics Eesti filiaal 
Tel: +372 6610 
Norge 
Teva Norway AS 
Tlf: +47 66775 
Ελλάδα 
Specifar A.B.E.E. 
Τηλ: +30 2118805 
Österreich 
ratiopharm Arzneimittel Vertriebs-GmbH 
Tel: +43 1970 
España 
Teva Pharma, S.L.U. 
Tel: +34 913873 
Polska 
Teva Pharmaceuticals Polska Sp. z o.o. 
Tel: +48 223459 
France 
Teva Santé 
Tél: +33 155917 
Portugal 
ratiopharm - Comércio e Indústria de Produtos 
Farmacêuticos, Lda. 
Tel: +351 214767 
Hrvatska 
Pliva Hrvatska d.o.o. 
Tel: +385 13720 
România 
Teva Pharmaceuticals S.R.L. 
Tel: +40 212306 
Ireland 
Teva Pharmaceuticals Ireland 
Tel: +44 2075407 
Slovenija 
Pliva Ljubljana d.o.o. 
Tel: +386 15890 
Ísland 
Alvogen ehf. 
Sími: +354 5222 
Slovenská republika 
TEVA Pharmaceuticals Slovakia s.r.o. 
Tel: +421 257267 
Italia 
Teva Italia S.r.l. 
Tel: +39 028917 
Suomi/Finland 
Teva Finland Oy 
Puh/Tel: +358 201805 
Κύπρος 
Specifar A.B.E.E. 
Ελλάδα 
Τηλ: +30 2118805 
Sverige 
Teva Sweden AB 
Tel: +46 42121 
Latvija 
UAB Teva Baltics filiāle Latvijā 
Tel: +371 67323 
United Kingdom (Northern Ireland) 
Teva Pharmaceuticals Ireland 
Ireland 
Tel: +44 2075407 </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>De kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>
<p>Indlægsseddel: Information til patienten </p>
<p>Memantine ratiopharm 20 mg filmovertrukne tabletter 
memantinhydrochlorid </p>
<p>Læs denne indlægsseddel grundigt, inden De begynder at tage dette lægemiddel, da den 
indeholder vigtige oplysninger. 
- Gem indlægssedlen. De kan få brug for at læse den igen. 
- Spørg lægen eller apotekspersonalet, hvis der er mere, De vil vide. 
- Lægen har ordineret Memantine ratiopharm til Dem personligt. Lad derfor være med at give 
medicinen til andre. Det kan være skadeligt for andre, selvom de har de samme symptomer, som 
De har. 
- Kontakt lægen eller apotekspersonalet, hvis De får bivirkninger, herunder bivirkninger, som 
ikke er nævnt i denne indlægsseddel. Se punkt 4. </p> </div>"""      



Instance: composition-pt-78817b35263746b79687cd6c5a122f9f
InstanceOf: CompositionUvEpi
Title: "Composition for memantine Package Leaflet"
Description:  "Composition for memantine Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/13/836/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp78817b35263746b79687cd6c5a122f9f)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - memantine"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #pt
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. FOLHETO INFORMATIVO"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. FOLHETO INFORMATIVO"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Folheto informativo: Informação para o utilizador"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Folheto informativo: Informação para o utilizador"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "O que contém este folheto"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "O que contém este folheto"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>O que contém este folheto </p>
<ol>
<li>O que é Memantina ratiopharm e para que é utilizado </li>
<li>O que precisa de saber antes de tomar Memantina ratiopharm </li>
<li>Como tomar Memantina ratiopharm </li>
<li>Efeitos indesejáveis possíveis </li>
<li>Como conservar Memantina ratiopharm </li>
<li>Conteúdo da embalagem e outras informações </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. O que é memantine e para que é utilizado"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. O que é memantine e para que é utilizado"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Como atua Memantina ratiopharm 
Memantina ratiopharm contém a substância ativa cloridrato de memantina. Pertence a um grupo de 
medicamentos conhecidos como fármacos antidemência. 
A perda de memória associada à doença de Alzheimer deve-se a uma perturbação dos sinais 
mensageiros no cérebro. O cérebro contém recetores do N-metil-D-aspartato (NMDA) envolvidos na 
transmissão de sinais nervosos importantes na aprendizagem e memória. Memantina ratiopharm 
pertence a um grupo de medicamentos denominados antagonistas dos recetores NMDA. Memantina 
ratiopharm atua nestes recetores, melhorando a transmissão dos sinais nervosos e a memória. </p>
<p>Para que é utilizado Memantina ratiopharm 
Memantina ratiopharm é utilizado para o tratamento de doentes com doença de Alzheimer moderada a 
grave. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. O que precisa de saber antes de tomar memantine"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. O que precisa de saber antes de tomar memantine"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Não tome Memantina ratiopharm </p>
<ul>
<li>se tem alergia ao cloridrato de memantina, amendoim ou soja ou a qualquer outro componente 
deste medicamento (indicados na secção 6) </li>
</ul>
<p>Advertências e precauções 
Fale com o seu médico ou farmacêutico antes de tomar Memantina ratiopharm </p>
<ul>
<li>
<p>se tiver uma história de epilepsia </p>
</li>
<li>
<p>se tiver tido um enfarte do miocárdio (ataque cardíaco) recente ou se sofrer de compromisso 
cardíaco congestivo ou de hipertensão (pressão arterial alta) não controlada. 
Nestas situações, o tratamento deve ser supervisionado cuidadosamente e os benefícios clínicos de 
Memantina ratiopharm devem ser avaliados pelo seu médico regularmente. </p>
</li>
</ul>
<p>Se sofrer de compromisso renal (problemas de rins), o seu médico deverá monitorizar cuidadosamente 
a sua função renal e, se necessário, adaptar as doses de memantina.  </p>
<p>A utilização simultânea de medicamentos designados por  </p>
<ul>
<li>
<p>amantadina (para o tratamento da doença de Parkinson),  </p>
</li>
<li>
<p>cetamina (uma substância usada geralmente como anestésico),  </p>
</li>
<li>
<p>dextrometorfano (usado geralmente para tratar a tosse) e  </p>
</li>
<li>
<p>outros antagonistas do NMDA 
deve ser evitada. </p>
</li>
</ul>
<p>Crianças e adolescentes 
Memantina ratiopharm não é recomendado para crianças e adolescentes com menos de 18 anos de 
idade. </p>
<p>Outros medicamentos e Memantina ratiopharm 
Informe o seu médico ou farmacêutico se estiver a tomar/utilizar, tiver tomado/utilizado recentemente 
ou se vier a tomar/utilizar outros medicamentos. </p>
<p>Em especial, os efeitos dos seguintes medicamentos podem ser alterados por Memantina ratiopharm e 
o seu médico poderá achar necessário ajustar as respetivas doses: </p>
<ul>
<li>
<p>amantadina, cetamina, dextrometorfano </p>
</li>
<li>
<p>dantroleno, baclofeno </p>
</li>
<li>
<p>cimetidina, ranitidina, procaínamida, quinidina, quinina, nicotina </p>
</li>
<li>
<p>hidroclorotiazida (ou qualquer outra combinação com hidroclorotiazida) </p>
</li>
<li>
<p>anticolinérgicos (substâncias geralmente utilizadas para tratar perturbações do movimento ou 
cãibras intestinais) </p>
</li>
<li>
<p>anticonvulsivantes (substâncias utilizadas para evitar ou atenuar convulsões) </p>
</li>
<li>
<p>barbitúricos (substâncias utilizadas geralmente para induzir o sono) </p>
</li>
<li>
<p>agonistas dopaminérgicos (substâncias como L-dopa, bromocriptina) </p>
</li>
<li>
<p>neurolépticos (substâncias utilizadas no tratamento de perturbações mentais). </p>
</li>
<li>
<p>anticoagulantes orais </p>
</li>
</ul>
<p>Se for hospitalizado, informe o seu médico de que está a tomar Memantina ratiopharm. </p>
<p>Memantina ratiopharm com alimentos e bebidas 
Deverá informar o seu médico caso tenha recentemente alterado ou pretenda alterar a sua dieta 
substancialmente (ex: de uma dieta normal para uma dieta estritamente vegetariana) ou se sofrer de 
estados de acidose tubular renal (ATR, um excesso de substâncias formadoras de ácido no sangue 
devido a uma disfunção renal (função dos rins debilitada)) ou infeções graves das vias urinárias 
(estrutura que transporta a urina), uma vez que poderá ser necessário que o seu médico faça um ajuste 
da dose do medicamento. </p>
<p>Gravidez e amamentação 
Se está grávida ou a amamentar, se pensa estar grávida ou planeia engravidar, consulte o seu médico 
ou farmacêutico antes de tomar este medicamento. </p>
<p>A utilização de memantina em grávidas não é recomendada.  </p>
<p>Mulheres que tomem Memantina ratiopharm não devem amamentar. </p>
<p>Condução de veículos e utilização de máquinas 
O seu médico irá informá-lo se a sua doença o impede de conduzir e utilizar máquinas com segurança. 
Para além disso, Memantina ratiopharm pode alterar a sua capacidade de reação, tornando a condução 
ou utilização de máquinas não apropriada.  </p>
<p>Memantina ratiopharm contém lactose ou lecitina de soja 
Memantina ratiopharm contém lactose. Se foi informado pelo seu médico que tem intolerância a alguns 
açúcares, contacte-o antes de tomar este medicamento. </p>
<p>Memantina ratiopharm contém lecitina de soja. Se for alérgico ao amendoim ou soja, não utilize este 
medicamento. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. Como tomar memantine"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Como tomar memantine"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tome este medicamento exatamente como indicado pelo seu médico. Fale com o seu médico ou 
farmacêutico se tiver dúvidas.  </p>
<p>Dose 
A dose recomendada de Memantina ratiopharm para doentes adultos e idosos é de 20 mg uma vez por 
dia. De forma a reduzir o risco de efeitos secundários, esta dose é atingida gradualmente segundo o 
seguinte esquema de tratamento diário: </p>
<p>semana 1 
metade de um comprimido revestido por película de 10 mg 
semana 2 
1 comprimido revestido por película de 10 mg 
semana 3 
1 comprimido revestido por película e meio de 10 mg 
semana 4 e seguintes 
2 comprimidos revestidos por película de 10 mg por dia </p>
<p>A dose inicial habitual corresponde a meio comprimido revestido por película, uma vez por dia 
(1x 5 mg) na primeira semana. Esta dose é aumentada para um comprimido revestido por película, uma 
vez por dia (1x 10 mg) na segunda semana e um comprimido revestido por película e meio, uma vez 
por dia, tomados na terceira semana. A partir da quarta semana, a dose habitual é de dois comprimidos 
revestidos por película, uma vez por dia (1x 20 mg). </p>
<p>O comprimido pode ser dividido em doses iguais. </p>
<p>Dose em doentes com compromisso da função renal 
Se tiver compromisso da função renal, o seu médico deverá decidir por uma dose adequada a essa 
situação. Neste caso, o seu médico deverá monitorizar a sua função renal regularmente.  </p>
<p>Administração 
Memantina ratiopharm deve ser administrado por via oral, uma vez por dia. Para tirar o maior 
benefício do seu medicamento, deve tomá-lo todos os dias, à mesma hora do dia. 
Os comprimidos revestidos por película devem ser engolidos com água. Os comprimidos revestidos por 
película podem ser administrados com ou sem alimentos. </p>
<p>Duração do tratamento 
Continue a tomar Memantina ratiopharm enquanto tiver um efeito benéfico. O seu médico deve 
avaliar o tratamento regularmente. </p>
<p>Se tomar mais Memantina ratiopharm do que deveria </p>
<ul>
<li>
<p>De uma forma geral, uma sobredosagem de Memantina ratiopharm não deve ser prejudicial. 
Poderá detetar um maior número de sintomas, tal como descrito na secção 4. “Efeitos 
secundários possíveis". </p>
</li>
<li>
<p>Se tomar uma dose muito elevada de Memantina ratiopharm, contacte o seu médico ou procure 
aconselhamento médico, uma vez que poderá necessitar de cuidados médicos. </p>
</li>
</ul>
<p>Caso se tenha esquecido de tomar Memantina ratiopharm </p>
<ul>
<li>
<p>Se se esquecer de tomar uma dose de Memantina ratiopharm, espere e tome a dose seguinte à 
hora habitual.  </p>
</li>
<li>
<p>Não tome uma dose a dobrar para compensar uma dose que se esqueceu de tomar. </p>
</li>
</ul>
<p>Caso ainda tenha dúvidas sobre a utilização deste medicamento, fale com o seu médico ou 
farmacêutico. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Efeitos indesejáveis possíveis"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Efeitos indesejáveis possíveis"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Como todos os medicamentos, este medicamento pode causar efeitos indesejáveis, embora estes não se 
manifestem em todas as pessoas. </p>
<p>De uma forma geral, os efeitos secundários observados são ligeiros a moderados.  </p>
<p>Frequentes (afeta 1 a 10 pessoas em 100): </p>
<ul>
<li>Dores de cabeça, sono, prisão de ventre, teste de função hepática aumentado, tonturas, 
perturbações do equilíbrio, falta de ar pressão arterial elevada e hipersensibilidade ao 
medicamento </li>
</ul>
<p>Pouco frequentes (afeta 1 a 10 pessoas em 1.000): </p>
<ul>
<li>Cansaço, infeções fúngicas, confusão, alucinações, vómitos, alterações na forma de andar, 
insuficiência cardíaca e coagulação sanguínea venosa (trombose, tromboembolia)  </li>
</ul>
<p>Muito raros (afeta menos de 1 pessoa em 10.000): </p>
<ul>
<li>Convulsões </li>
</ul>
<p>Desconhecido (a frequência não pode ser estimada a partir dos dados disponíveis): </p>
<ul>
<li>Inflamação do pâncreas, inflamação do fígado (hepatite) e reações psicóticas </li>
</ul>
<p>A doença de Alzheimer tem sido associada a depressão, ideação suicida e suicídio. Estes efeitos têm 
sido notificados com doentes tratados com memantina. </p>
<p>Comunicação de efeitos indesejáveis 
Se tiver quaisquer efeitos indesejáveis, incluindo possíveis efeitos indesejáveis não indicados neste 
folheto, fale com o seu médico ou farmacêutico. Também poderá comunicar efeitos indesejáveis 
diretamente através do sistema nacional de notificação mencionado no Apêndice V. Ao comunicar 
efeitos indesejáveis, estará a ajudar a fornecer mais informações sobre a segurança deste medicamento. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. Como conservar memantine"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Como conservar memantine"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Manter este medicamento fora da vista e do alcance das crianças. </p>
<p>Não utilize este medicamento após o prazo de validade impresso na embalagem exterior e no blister, 
após EXP. O prazo de validade corresponde ao último dia do mês indicado. </p>
<p>Embalagens blister 
Não conservar acima de 25 °C. </p>
<p>Frascos de PEAD 
O medicamento não necessita de quaisquer precauções especiais de conservação. 
Prazo de validade após abertura do recipiente: 6 meses </p>
<p>Não deite fora quaisquer medicamentos na canalização ou no lixo doméstico. Pergunte ao seu 
farmacêutico como deitar fora os medicamentos que já não utiliza. Estas medidas ajudarão a proteger 
o ambiente. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Conteúdo da embalagem e outras informações"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Conteúdo da embalagem e outras informações"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Qual a composição de Memantina ratiopharm 
- A substância ativa é cloridrato de memantina. 
Cada comprimido revestido por película contém 10 mg de cloridrato de memantina, equivalente 
a 8,31 mg de memantina. </p>
<ul>
<li>Os outros componentes são: 
Núcleo do comprimido 
Celulose microcristalina (E 460), amido pré-gelatinizado (E 1404), lactose, sílica coloidal 
anidra (E 551), e estearato de magnésio (E 470B).<br />
Revestimento 
Polisorbato 80 (E 433), álcool polivinílico (E 1203), dióxido de titânio (E 171), talco (E 553b), 
lecitina de soja (E 322), goma xantana (E 415). </li>
</ul>
<p>Qual o aspeto de Memantina ratiopharm e conteúdo da embalagem 
Comprimidos brancos a esbranquiçados, em forma de cápsula, biconvexos, com uma ranhura num lado e 
com “10" gravado no outro lado. </p>
<p>Memantina ratiopharm é apresentado em embalagens de 10, 14, 21, 28, 30, 42, 50, 56, 98, 100 e 
112 comprimidos revestidos por película. </p>
<p>É possível que não sejam comercializadas todas as apresentações. </p>
<p>Titular da Autorização de Introdução no Mercado<br />
ratiopharm GmbH 
Graf-Arco-Straße 3 
89079 Ulm 
Alemanha </p>
<p>Fabricante 
Merckle GmbH 
Ludwig-Merckle-Straße 3 
89143 Blaubeuren 
Alemanha </p>
<p>TEVA Pharmaceutical Works Private Limited Company 
Pallagi út 13, 4042 Debrecen 
Hungria </p>
<p>HBM Pharma s.r.o. 
Slabinská 30, 03680 Martin 
Eslováquia </p>
<p>Para quaisquer informações sobre este medicamento, queira contactar o representante local do Titular 
da Autorização de Introdução no Mercado. </p>
<p>België/Belgique/Belgien 
Teva Pharma Belgium N.V./S.A./AG 
Tél/Tel: +32 38207 
Lietuva 
UAB Teva Baltics 
Tel: +370 52660 
България 
Тева Фарма ЕАД 
Тел: +359 24899 
Luxembourg/Luxemburg 
ratiopharm GmbH 
Allemagne/Deutschland 
Tél/Tel: +49 73140 </p>
<p>Česká republika 
Teva Pharmaceuticals CR, s.r.o. 
Tel: +420 251007 
Magyarország 
Teva Gyógyszergyár Zrt. 
Tel: +36 12886 
Danmark 
Teva Denmark A/S 
Tlf: +45 44985 
Malta 
Teva Pharmaceuticals Ireland 
L-Irlanda 
Tel: +44 2075407 
Deutschland 
ratiopharm GmbH 
Tel: +49 73140 
Nederland 
Teva Nederland B.V. 
Tel: +31 8000228 
Eesti 
UAB Teva Baltics Eesti filiaal 
Tel: +372 6610 
Norge 
Teva Norway AS 
Tlf: +47 66775 
Ελλάδα 
Specifar A.B.E.E. 
Τηλ: +30 2118805 
Österreich 
ratiopharm Arzneimittel Vertriebs-GmbH 
Tel: +43 1970 
España 
Teva Pharma, S.L.U. 
Tel: +34 913873 
Polska 
Teva Pharmaceuticals Polska Sp. z o.o. 
Tel: +48 223459 
France 
Teva Santé 
Tél: +33 155917 
Portugal 
ratiopharm - Comércio e Indústria de Produtos 
Farmacêuticos, Lda. 
Tel: +351 214767 
Hrvatska 
Pliva Hrvatska d.o.o. 
Tel: +385 13720 
România 
Teva Pharmaceuticals S.R.L. 
Tel: +40 212306 
Ireland 
Teva Pharmaceuticals Ireland 
Tel: +44 2075407 
Slovenija 
Pliva Ljubljana d.o.o. 
Tel: +386 15890 
Ísland 
Alvogen ehf. 
Sími: +354 5222 
Slovenská republika 
TEVA Pharmaceuticals Slovakia s.r.o. 
Tel: +421 257267 
Italia 
Teva Italia S.r.l. 
Tel: +39 028917 
Suomi/Finland 
Teva Finland Oy 
Puh/Tel: +358 201805 
Κύπρος 
Specifar A.B.E.E. 
Ελλάδα 
Τηλ: +30 2118805 
Sverige 
Teva Sweden AB 
Tel: +46 42121 
Latvija 
UAB Teva Baltics filiāle Latvijā 
Tel: +371 67323 
United Kingdom (Northern Ireland) 
Teva Pharmaceuticals Ireland 
Ireland 
Tel: +44 2075407 </p>
<p>Este folheto foi revisto pela última vez em  </p>
<p>Está disponível informação pormenorizada sobre este medicamento no sítio da internet da Agência </p> </div>"""      





                    
Instance: bundlepackageleaflet-en-78817b35263746b79687cd6c5a122f9f
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for memantine Package Leaflet for language en"
Description: "ePI document Bundle for memantine Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-78817b35263746b79687cd6c5a122f9f"
* entry[0].resource = composition-en-78817b35263746b79687cd6c5a122f9f

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp78817b35263746b79687cd6c5a122f9f"
* entry[=].resource = mp78817b35263746b79687cd6c5a122f9f
                            
                    
Instance: bundlepackageleaflet-da-78817b35263746b79687cd6c5a122f9f
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for memantine Package Leaflet for language da"
Description: "ePI document Bundle for memantine Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-78817b35263746b79687cd6c5a122f9f"
* entry[0].resource = composition-da-78817b35263746b79687cd6c5a122f9f

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp78817b35263746b79687cd6c5a122f9f"
* entry[=].resource = mp78817b35263746b79687cd6c5a122f9f
                            
                    
Instance: bundlepackageleaflet-pt-78817b35263746b79687cd6c5a122f9f
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for memantine Package Leaflet for language pt"
Description: "ePI document Bundle for memantine Package Leaflet for language pt"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #pt

// Composition
* entry[0].fullUrl = "Composition/composition-pt-78817b35263746b79687cd6c5a122f9f"
* entry[0].resource = composition-pt-78817b35263746b79687cd6c5a122f9f

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp78817b35263746b79687cd6c5a122f9f"
* entry[=].resource = mp78817b35263746b79687cd6c5a122f9f
                            
                    



Instance: mp78817b35263746b79687cd6c5a122f9f
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Memantine ratiopharm 10 mg film-coated tablets"
Description: "Memantine ratiopharm 10 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/13/836/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Memantine ratiopharm 10 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 78817b35263746b79687cd6c5a122f9fListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "memantine"

* status = #current
* mode = #working

* title = "List of all ePIs associated with memantine"

* subject = Reference(mp78817b35263746b79687cd6c5a122f9f)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#memantine "memantine"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-78817b35263746b79687cd6c5a122f9f) // memantine en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-78817b35263746b79687cd6c5a122f9f) // memantine da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-pt-78817b35263746b79687cd6c5a122f9f) // memantine pt
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "pt"




Instance: List-78817b35263746b79687cd6c5a122f9f
InstanceOf: List

* insert 78817b35263746b79687cd6c5a122f9fListRuleset
    